|
US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
ATE463572T1
(de)
*
|
2003-12-03 |
2010-04-15 |
Univ Rochester |
Rekombinanter faktor viii mit erhöhter spezifischer aktivität
|
|
ES2560657T3
(es)
|
2004-01-08 |
2016-02-22 |
Ratiopharm Gmbh |
Glicosilación con unión en O de péptidos G-CSF
|
|
EP1771066A2
(en)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
|
|
EP2586456B1
(en)
|
2004-10-29 |
2016-01-20 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (FGF)
|
|
MX2007008229A
(es)
|
2005-01-10 |
2007-09-11 |
Neose Technologies Inc |
Factor estimulador de colonias de granulocitos glicopegilado.
|
|
EP1871795A4
(en)
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
|
|
WO2006108590A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation factor viii with enhanced stability and its derivates
|
|
EP2975135A1
(en)
|
2005-05-25 |
2016-01-20 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
JP2009518345A
(ja)
|
2005-12-07 |
2009-05-07 |
テフニーシェ ウニヴェルジテート ミュンヘン |
因子ｖｉｉｉおよび因子ｖｉｉｉ様タンパク質に対する小型ペプチドおよびペプチド模倣物の親和性リガンド
|
|
WO2008005847A2
(en)
*
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
|
US20090203077A1
(en)
*
|
2006-06-30 |
2009-08-13 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
|
EP2049144B8
(en)
|
2006-07-21 |
2015-02-18 |
ratiopharm GmbH |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
|
EP2126106B1
(en)
|
2007-02-23 |
2017-09-06 |
Sk Chemicals Co., Ltd. |
Process for producing and purifying factor viii and its derivatives
|
|
EA017770B1
(ru)
|
2007-04-03 |
2013-03-29 |
Биодженерикс Аг |
Способы лечения с использованием гликопэгилированного g-csf
|
|
JP5876649B2
(ja)
|
2007-06-12 |
2016-03-02 |
ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ |
ヌクレオチド糖の改良製造法
|
|
MX2010004813A
(es)
*
|
2007-11-01 |
2010-10-04 |
Univ Rochester |
Factor viii recombinante que tiene estabilidad incrementada.
|
|
WO2009089396A2
(en)
*
|
2008-01-08 |
2009-07-16 |
Neose Technologies, Inc. |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
|
DK2257311T3
(da)
|
2008-02-27 |
2014-06-30 |
Novo Nordisk As |
Konjugerede Faktor VIII-Molekyler
|
|
JP5997443B2
(ja)
*
|
2008-05-16 |
2016-09-28 |
バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ |
標的化凝固因子およびそれを使用する方法
|
|
PT3178835T
(pt)
|
2009-02-03 |
2019-06-19 |
Amunix Pharmaceuticals Inc |
Polipéptidos recombinantes estendidos e composições que compreendem os mesmos
|
|
CN102741275B
(zh)
|
2009-08-24 |
2016-08-03 |
阿穆尼克斯运营公司 |
凝血因子ix组合物及其制备和使用方法
|
|
ES2717902T5
(es)
|
2009-10-02 |
2022-11-29 |
Childrens Hospital Philadelphia |
Composiciones y procedimientos para mejorar la función del factor VIII de coagulación
|
|
PT2506868T
(pt)
|
2009-12-06 |
2018-02-23 |
Bioverativ Therapeutics Inc |
Polipéptidos quiméricos e hibridos de factor viii-fc, e métodos de utilização dos mesmos
|
|
WO2012006623A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Systems for factor viii processing and methods thereof
|
|
EP2591006B1
(en)
|
2010-07-09 |
2019-04-24 |
Bioverativ Therapeutics Inc. |
Processable single chain molecules and polypeptides made using same
|
|
EP2635297B1
(en)
*
|
2010-11-05 |
2019-02-27 |
Baxalta GmbH |
A new variant of antihemophilic factor viii having increased specific activity
|
|
AU2012267484B2
(en)
|
2011-06-10 |
2017-03-23 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
US10010622B2
(en)
|
2011-07-08 |
2018-07-03 |
Bioverativ Therapeutics Inc. |
Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
|
|
EP2737311B1
(en)
|
2011-07-25 |
2020-12-02 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
|
US9511123B2
(en)
|
2011-10-18 |
2016-12-06 |
Csl Behring Gmbh |
Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
|
|
ES2600081T3
(es)
|
2011-10-18 |
2017-02-07 |
Csl Behring Gmbh |
Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII
|
|
KR20140084208A
(ko)
|
2011-10-18 |
2014-07-04 |
시에스엘 리미티드 |
정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
|
|
DK2804623T3
(da)
|
2012-01-12 |
2019-11-11 |
Bioverativ Therapeutics Inc |
Kimære faktor viii-polypeptider og anvendelser deraf
|
|
EA029560B1
(ru)
|
2012-01-12 |
2018-04-30 |
Байоджен Эмэй Инк. |
Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта
|
|
EA201491388A1
(ru)
|
2012-02-15 |
2015-01-30 |
Байоджен Айдек Ма Инк. |
Рекомбинантные белки фактора viii
|
|
CN119192402A
(zh)
*
|
2012-02-15 |
2024-12-27 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
WO2013185114A2
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
|
JP2015521589A
(ja)
|
2012-06-08 |
2015-07-30 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
プロコアグラント化合物
|
|
EP2870250B2
(en)
|
2012-07-06 |
2022-06-29 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
|
KR101395736B1
(ko)
*
|
2012-07-10 |
2014-05-16 |
아주대학교산학협력단 |
인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
|
|
DK2882450T3
(da)
|
2012-07-11 |
2020-02-24 |
Bioverativ Therapeutics Inc |
Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
|
|
HK1212882A1
(zh)
|
2012-07-25 |
2016-06-24 |
Bioverativ Therapeutics Inc. |
血液因子的監測分析及其用途
|
|
HK1213767A1
(zh)
|
2012-10-18 |
2016-07-15 |
Bioverativ Therapeutics Inc. |
使用固定劑量凝血因子的方法
|
|
HK1214539A1
(zh)
|
2012-10-30 |
2016-07-29 |
Bioverativ Therapeutics Inc. |
應用viii因子多肽的方法
|
|
ES2848703T5
(es)
|
2013-02-15 |
2024-06-25 |
Bioverativ Therapeutics Inc |
Gen del factor VIII optimizado
|
|
AU2014228938B2
(en)
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
|
ES2926798T3
(es)
|
2013-03-15 |
2022-10-28 |
Bioverativ Therapeutics Inc |
Formulaciones de polipéptido de factor VIII
|
|
ES2657291T3
(es)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
|
US20160251408A1
(en)
|
2013-06-28 |
2016-09-01 |
Biogen Ma Inc. |
Thrombin cleavable linker with xten and its uses thereof
|
|
WO2015021423A2
(en)
|
2013-08-08 |
2015-02-12 |
Biogen Idec Ma Inc. |
Purification of chimeric fviii molecules
|
|
EP3033097B1
(en)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
|
US10584147B2
(en)
|
2013-11-08 |
2020-03-10 |
Biovertiv Therapeutics Inc. |
Procoagulant fusion compound
|
|
EP3082848B1
(en)
|
2013-12-06 |
2023-10-18 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
|
CN116621991A
(zh)
|
2014-01-10 |
2023-08-22 |
比奥贝拉蒂治疗公司 |
因子viii嵌合蛋白及其用途
|
|
WO2015107222A1
(en)
*
|
2014-01-20 |
2015-07-23 |
Octapharma Ag |
A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
|
|
EP3102589A1
(en)
|
2014-02-04 |
2016-12-14 |
Biogen MA Inc. |
Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
|
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
|
SG11201700550YA
(en)
|
2014-08-04 |
2017-02-27 |
Csl Ltd |
Factor viii formulation
|
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
|
BR112017018468A2
(pt)
|
2015-03-06 |
2018-04-17 |
Csl Behring Recombinant Facility Ag |
fator de von willebrand modificado com meia-vida aumentada
|
|
SG10201910896UA
(en)
|
2015-05-22 |
2020-01-30 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
JP6651548B2
(ja)
|
2015-05-22 |
2020-02-19 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
改変フォン・ヴィルブランド因子を製造するための方法
|
|
UA126016C2
(uk)
|
2015-08-03 |
2022-08-03 |
Біовератів Терапеутікс Інк. |
Злитий білок фактора іх
|
|
WO2017050820A1
(en)
*
|
2015-09-22 |
2017-03-30 |
Novo Nordisk A/S |
Fviii fusion proteins
|
|
KR102404550B1
(ko)
|
2015-11-13 |
2022-05-31 |
다케다 야쿠힌 고교 가부시키가이샤 |
A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터
|
|
CN108884145B
(zh)
|
2015-11-13 |
2023-08-22 |
武田药品工业株式会社 |
用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
|
|
MX2018008337A
(es)
|
2016-01-07 |
2018-09-17 |
CSL Behring Lengnau AG |
Factor de von willebrand truncado mutado.
|
|
PL3411478T3
(pl)
|
2016-02-01 |
2022-10-03 |
Bioverativ Therapeutics Inc. |
Geny zoptymalizowanego czynnika VIII
|
|
US11046749B2
(en)
|
2016-06-24 |
2021-06-29 |
Mogam Institute For Biomedical Research |
Chimera protein comprising FVIII and vWF factors, and use thereof
|
|
JP7235511B2
(ja)
|
2016-06-24 |
2023-03-08 |
モガム・インスティテュート・フォー・バイオメディカル・リサーチ |
組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
|
|
JP6351679B2
(ja)
*
|
2016-09-30 |
2018-07-04 |
エスケー ケミカルズ カンパニー リミテッド |
第ｖｉｉｉ因子とその誘導体の製造及び精製方法
|
|
CN109922824A
(zh)
|
2016-11-11 |
2019-06-21 |
康诺贝林伦瑙有限公司 |
用于治疗血友病的截短的冯维勒布兰德因子多肽
|
|
SG11201903954WA
(en)
|
2016-11-11 |
2019-05-30 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
|
|
JP2019536794A
(ja)
|
2016-12-02 |
2019-12-19 |
バイオベラティブ セラピューティクス インコーポレイテッド |
凝固因子に対する免疫寛容を誘導する方法
|
|
EP3548066A1
(en)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
|
WO2018234518A1
(en)
|
2017-06-22 |
2018-12-27 |
CSL Behring Lengnau AG |
MODULATION OF IMMUNOGENICITY OF FVIII BY VWF TRONQUÉ
|
|
IL272463B1
(en)
|
2017-08-09 |
2025-08-01 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and their uses
|
|
CN111295094A
(zh)
|
2017-10-09 |
2020-06-16 |
泰尔茂比司特生物技术有限公司 |
冻干容器及使用冻干容器的方法
|
|
CN111918674A
(zh)
|
2018-02-01 |
2020-11-10 |
比奥维拉迪维治疗股份有限公司 |
表达因子viii的慢病毒载体的用途
|
|
IL277713B2
(en)
|
2018-04-04 |
2024-09-01 |
Sigilon Therapeutics Inc |
Implantable particles and related methods
|
|
US12030925B2
(en)
|
2018-05-18 |
2024-07-09 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia A
|
|
AU2019306194A1
(en)
|
2018-07-16 |
2021-02-04 |
Baxalta GmbH |
Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression
|
|
CN119955796A
(zh)
|
2018-08-09 |
2025-05-09 |
比奥维拉迪维治疗股份有限公司 |
核酸分子及其用于非病毒基因疗法的用途
|
|
EP3852780A1
(en)
*
|
2018-09-19 |
2021-07-28 |
Cell Machines, Inc. |
Methods and compositions related to improved factor viii long half-life coagulation complexes
|
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
|
TWI851647B
(zh)
|
2019-01-16 |
2024-08-11 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
|
AU2020221340A1
(en)
*
|
2019-02-15 |
2021-09-16 |
Bayer Healthcare Llc |
Gene editing for hemophilia A with improved Factor VIII expression
|
|
WO2020185909A2
(en)
|
2019-03-14 |
2020-09-17 |
Terumo Bct Biotechnologies, Llc |
Lyophilization loading tray assembly and system
|
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
|
MX2021009814A
(es)
*
|
2019-06-05 |
2022-10-27 |
Crispr Therapeutics Ag |
Edición de genes para hemofilia a con expresión mejorada del factor viii.
|
|
MX2021015897A
(es)
|
2019-06-19 |
2022-04-18 |
Bioverativ Therapeutics Inc |
Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja.
|
|
US20220389082A1
(en)
|
2019-07-04 |
2022-12-08 |
CSL Behring Lengnau AG |
A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
|
|
CN115279896A
(zh)
|
2019-09-30 |
2022-11-01 |
比奥维拉迪维治疗股份有限公司 |
慢病毒载体配制品
|
|
US20220348637A1
(en)
|
2019-11-11 |
2022-11-03 |
CSL Behring Lengnau AG |
Polypeptides for inducing tolerance to factor viii
|
|
WO2021119357A2
(en)
|
2019-12-12 |
2021-06-17 |
Baxalta Incorporated |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
|
JP7681268B2
(ja)
*
|
2020-03-30 |
2025-05-22 |
シスメックス株式会社 |
血液凝固活性の測定方法
|
|
BR112022026127A2
(pt)
|
2020-06-24 |
2023-01-17 |
Bioverativ Therapeutics Inc |
Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
|
|
US20240269241A1
(en)
|
2021-06-14 |
2024-08-15 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
|
US20230084036A1
(en)
|
2021-08-23 |
2023-03-16 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
|
IL311725A
(en)
|
2021-09-30 |
2024-05-01 |
Bioverativ Therapeutics Inc |
Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
|
|
EP4602155A1
(en)
|
2022-10-11 |
2025-08-20 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|
|
TW202517669A
(zh)
|
2023-07-05 |
2025-05-01 |
日商武田藥品工業股份有限公司 |
用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體
|